Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Real-world comparative outcomes of pola-R-CHP versus R-CHOP in patients with diffuse large B-cell lymphoma

View Full Paper
Ask AI
Bookmark
Share

Authors

MCMahija CheekatiASAnthony Stack

Discussion

Loading...

Member takes

Overview

Retrospective cohort study shows improved overall survival in DLBCL with Pola-R-CHP, indicating less hospitalization and fewer complications.

Key Points

  • This research aims to compare clinical outcomes of Pola-R-CHP and R-CHOP regimens in patients with DLBCL.
  • Conducted a retrospective cohort study using data from the TriNetX database
  • Applied propensity score matching for confounder adjustment
  • Performed time-to-event analysis using Cox proportional hazards models
  • Pola-R-CHP improved overall survival compared to R-CHOP (HR 0.653, p<0.0006)
  • Median overall survival for R-CHOP was 153.8 months; for Pola-R-CHP, it was not met
  • Lower rates of hospitalization (RR 0.654) and acute kidney injury (RR 0.621) observed in Pola-R-CHP recipients

Cite This Study

Cheekati et al. (2025) studied this question.

synapsesocial.com/papers/69362f5a4fa91c937236db7dhttps://doi.org/10.1182/blood-2025-2759
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Comparative real-world safety outcomes of Pola-R-CHP versus R-CHOP in high-grade diffuse large B-cell lymphoma (DLBCL): A TriNetX study.2026
  2. 2Real-world outcomes of polatuzumab vedotin plus R-CHP versus R-CHOP in newly diagnosed diffuse large B-cell lymphoma: A propensity-matched analysis.2026
  3. 3Real-World Comparative Analysis of Polatuzumab Vedotin–Based Pola-R-CHP Versus Standard R-CHOP in Diffuse Large B-Cell Lymphoma: A Propensity Score–Matched Cohort Study2025
  4. 4Real-world use of Pola-R-CHP for untreated diffuse large B-cell lymphoma (DLBCL): A systematic literature review2025
  5. 5Five-Year Outcomes of the POLARIX Study Comparing Pola-R-CHP and R-CHOP in Patients With Diffuse Large B-Cell Lymphoma.2025 · 42 citations